[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632911":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":29,"centralContacts":36,"locations":45,"responsibleParty":63,"collaborators":29,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":29,"enrollmentInfo":75,"targetDuration":29,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":48,"whyStopped":29,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"China Medical University, China","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"No nutritional intervention","PLACEBO_COMPARATOR","No intervention was applied as a negative control to validate the experimental effect.",[13],"Other: Administration of placebo as a negative control to validate experimental efficacy",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard Nutritional Intervention","ACTIVE_COMPARATOR","Standard intervention was administered as a positive control to validate experimental efficacy.",[19],"Drug: Standard nutritional intervention was administered as a positive control to validate experimental efficacy.",{"label":21,"type":16,"description":22,"interventionNames":23},"Enhanced Nutritional Intervention","Validation of intervention efficacy through enhanced intervention in nutritionally high-risk patients",[24],"Drug: Validation of intervention efficacy through enhanced intervention in nutritionally high-risk patients",[26,30,33],{"type":27,"name":22,"description":22,"armGroupLabels":28,"otherNames":29},"DRUG",[21],null,{"type":27,"name":31,"description":31,"armGroupLabels":32,"otherNames":29},"Standard nutritional intervention was administered as a positive control to validate experimental efficacy.",[15],{"type":6,"name":34,"description":34,"armGroupLabels":35,"otherNames":29},"Administration of placebo as a negative control to validate experimental efficacy",[9],[37,42],{"name":38,"role":39,"phone":40,"phoneExt":29,"email":41},"Hanwen Liu","CONTACT","+86 18941960007","X18941960007@126.com",{"name":43,"role":39,"phone":44,"phoneExt":29,"email":41},"XiaoXu Liu","+86 18042901898",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":29,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"The First Affiliated Hospital of China Medical University","RECRUITING","Shenyang","Liaoning","China","CN",{"type":54,"coordinates":55},"Point",[56,57],123.43278,41.79222,{"lat":57,"lon":56},[60],{"name":61,"role":39,"phone":40,"phoneExt":29,"email":62},"Kai Li","cmu_likai@163.com",{"type":64,"investigatorFullName":61,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"PRINCIPAL_INVESTIGATOR","Chief Physician of Gastrointestinal Oncology Surgery, The First Affiliated Hospital of China Medical University","100632911","study-on-the-pathogenesis-and-reversal-strategies-of-cancer-cachexia-based-on-multi-omics-100632911",false,"NCT07519837","Study on the Pathogenesis and Reversal Strategies of Cancer Cachexia Based on Multi-Omics","PRCC-MO","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Signed informed consent form and voluntary participation in this study\n* Histologically and\u002For cytologically confirmed diagnosis of cancer\n* Patients with gastrointestinal malignancies, including:\n* Esophageal cancer\n* Hepatocellular carcinoma\n* Gastric cancer\n* Cholangiocarcinoma\n* Patients undergoing histopathological examination of primary lesion biopsy or gastrointestinal endoscopic biopsy\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Presence of contraindications to surgery\n* Cognitive dysfunction, psychiatric disorders, impaired consciousness, or inability\u002Funwillingness to cooperate\n* Presence of two or more concurrent primary tumors","ALL","18 Years",{"count":76,"type":77},1000,"ESTIMATED","INTERVENTIONAL",[80],"NA","Cancer cachexia is a complex systemic metabolic syndrome with high incidence and mortality rates, significantly impacting the prognosis and survival of cancer patients.Current clinical comprehensive intervention approaches can only provide transient symptom relief and fail to fundamentally block or reverse muscle and fat loss. The core challenge lies in the extreme complexity of this pathological mechanism and the lack of early biomarkers.To overcome the limitations of traditional single-dimensional research approaches, this study proposes a combined analysis method utilizing \"multi-omics\" (imaging omics, pathological omics, metabolomics, and metagenomics) to construct a panoramic systemic model spanning macroscopic clinical manifestations and microscopic molecular processes. The aim is to comprehensively elucidate the pathogenesis and metabolic pathways of cachexia, thereby precisely identifying potential therapeutic targets capable of reversing this pathological process.",[83],"Cachexia; Cancer; Sarcopenia",[85,86,87],"cancer associated cachexia","Multi-omics Integrated Analysis","Mechanism Exploration and Reversal Strategy Research","2026-04-02",{"date":90,"type":91},"2026-04-09","ACTUAL",{"date":93,"type":91},"2026-03-18",{"date":95,"type":77},"2028-03-20",{"name":5,"class":6},1]